Document text
BioNTech SE 05/07/2021
An der Goldgrube 12
Mainz N/A
Germany 55131215-280-5503
COVID-19 Vaccine (BNT162, PF-07302048) 019736
Prophylactic immunization against COVID-19 in adults
16 years of age
BB-IND 013812, BB-IND 013278, BLA 125549
0 3 2 4
3
FDA-CBER-2021 5683-1072496
Özlem Türeci, MD, Chief Medical Officer, BioNTech SE
Özlem Türeci, MD, Chief Medical Officer, BioNTech SE
Neda Aghajani Memar, Pharm.D., Director, Pfizer Global Regulatory Affairs - Vaccines
212-733-2613 (845) 474-3500
235 East 42nd Street
219/9/69
New York NY
United States of America [email protected]
05/07/2021
United States of America
Elisa Harkins TullDigitally signed by Elisa Harkins Tull
DN o=Pfizer Inc, cn=Elisa Harkins Tull
Reason I attest to the accuracy and integrity of
this document
Date 2021.05.07 09 25 21 -04'00'
3
FDA-CBER-2021-5683-1072497
3
FDA-CBER-2021-5683-1072498